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Abstract 
 
Stan Heptinstall’s contributions to platelet research covered organising meetings at 
the national and European level as well as starting and maintaining the journal 
‘Platelets’. The major part of his research addressed problems of inhibition of platelet 
receptors and the effects of this on patient health. In particular, the effects of P2Y12 
inhibitors on patients, with acute cardiovascular problems was a major focus. Other 
studies included the effects of feverfew (Tanacetum parthenium) extracts on 
platelets, of direct anti IIb/IIIa receptor (IIb3) inhibitors and of prostanoids on 
platelet function. Recently, methods for assessing the effectiveness of platelet 
inhibition were investigated. 
 
Introduction 
 
Stan has contributed to platelet research on a number of levels. He has been 
involved in a large amount of basic and clinical research on platelets and adjoining 
areas and these will be discussed below but his contributions to what may be called 
the sociology of platelet research are also large and need to be considered too 
because in the long term they may have had even greater effects. 
We are now used to research being organised on a European and international level 
but when Stan began his research, apart from a few major areas such as CERN, 
astronomy and space research where it was difficult for individual countries to make 
meaningful contributions because of the scale required, most research was done 
essentially at a local, national level. This does not mean that there was no 
international collaboration in the “smaller” areas such as platelet research but this 
was often organised on a very ad hoc basis – but was no less effective for that. Stan 
saw that there were problems, particularly in respect of people living behind the – 
then – Iron Curtain, and because many of these faced severe travel restrictions. One 
of the main ways in which he and his colleagues tried to help was by encouraging 
Western researchers to participate in the Erfurt Conferences organised regularly by 
DDR colleagues and also attended by other Eastern European colleagues, even 
from as far away as Russia. After the lifting of travel restrictions in 1989 these 
meetings were well attended by researchers from across Europe and even further 
afield and continued for many years. More recently there has been a trend to 
consolidate platelet related meetings and to hold them in various sites across 
Europe, often together with national meetings. 
Another major initiative that Stan took was, of course, as inaugural editor in the 
launching of the journal “Platelets” in 1990. Professor Dimitri Mikailidis had 
persuaded Churchill Livingston to publish this new journal and Stan was proposed as 
editor. Stan discussed this with many of us before going ahead. He had several 
motivations: There was no journal devoted solely to platelet research, all the other 
journals had a broader basis either in thrombosis and haemostasis or in 
haematology and several around that time, perhaps lacking forceful enough editors, 
had lost support and influence. In addition, Stan wanted to provide a platform for 
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authors outside the mainstream and also in developing countries to help them reach 
a bigger audience and to encourage them in their research. As part of this he 
regularly published abstracts from platelet meetings such as those mentioned above. 
The first Erfurt Conference Abstracts to appear in Platelets were those for the 4th 
Meeting in 1992 [1]. For a number of years it was difficult to attract adequate 
numbers of papers of interest to readers (perhaps because papers in the platelet 
area did not expand as rapidly as the scientific literature in general) but the situation 
improved and today the journal is in the “happy” situation of receiving more 
reasonable quality papers than it has space to publish and must therefore reject 
quite a few. However, it has indeed managed to extend its authors to a wide range of 
countries previously poorly represented. There was a major scare at the end of 1995 
when the then publisher decided to stop but Stan managed to find a new publisher 
and continue and since then the journal has gone from strength to strength. Thus, 
Stan has managed to achieve his major goal in leaving “Platelets” as a healthy 
journal meeting most of his objectives. The detailed history of Platelets is dealt with 
by Alan Nurden in the accompanying chapter. 
 
Since 1985 Stan has been professor of thrombosis and haemostasis and is the main 
coordinator of the Clinical Sciences Homebase at the University of Nottingham, 
which contributes to the  teaching of more than 50 third year medical students 
studying  for a Batchelor of Medical Sciences degree. In his recent role as head of 
the Division 
of Cardiovascular Medicine, he was involved in employing, mentoring, and guiding 
staff  working closely with their National Health Service colleagues at both 
Nottingham City Hospital and Nottingham University Hospital as well as with 
colleagues involved in basic research. He remains an active member of the 
International Society for Thrombosis and Haemostasis as well as the British Society 
for Haemostasis and Thrombosis, where he was an honorary secretary and also had 
a  turn as president. 
 
 
Turning to his research interests, after a few years working on bacterial cell wall 
components, the subject of his doctoral thesis, Stan settled down essentially to what 
would be his long term interest. Of course, this concerned platelets but in particular it 
concerned how platelet receptor inhibition could protect patients, people at high risk 
or even ‘normal’ individuals against thrombosis and other cardiovascular diseases 
without the major side effect of an increased tendency to bleeding. One of the first 
breakthroughs in this area had been the demonstration that aspirin protects patients 
against thrombosis, later shown to be via inhibition of platelet thromboxane 
synthesis. That this was possible awakened considerable interest in alternative 
methods of inhibiting platelet activation. 
 
Following the demonstration that the bleeding disorder Glanzmann’s thrombasthenia 
was caused by a defect or deficiency in the major platelet integrin IIb3, preventing 
platelet aggregation via fibrinogen, considerable effort was exerted to produce 
synthetic inhibitors to cause a similar but controllable blockage. This led to the 
development of peptide or antibody inhibitors of IIb3 and then small molecule 
inhibitors, used extensively for prevention of thrombosis in acute problems, 
particularly in surgery. The hunt was then on for small molecule inhibitors that could 
be used for treatment of chronic disease. 
 
Already in 1975 the thienopyridine anti-thrombotic drug ticlopidine was shown to be 
an efficient platelet aggregation inhibitor but following side effects was replaced by 
clopidogrel in 1987 and, in 2001, their target was shown to be the ADP receptor 
P2Y12. The question arose as to how well each category and combination of 
inhibitors worked in patients. More recently, a major question has been why part of 
the population does not respond well to either treatment and may need different 
dosing. This is often referred to as resistance. The newest drug in this thienopyridine 
class is prasugrel with clear dosage, efficacy and compliance advantages. 
 
Stan’s most cited paper (1994) is a large clinical study (cited 2241 times, as I write) 
dealing with thrombosis prevention in cohorts of patients and controls when treated 
with an anti-platelet regimen (aspirin) for longer periods (one to several years) and 
indicating that, at least in patients with cardiovascular problems, longer than 
conventional treatment did lead to increased protection [2]. However, there was little 
effect in controls (maybe the level of events was too low for statistically relevant 
results?). This was one of the first papers to indicate that extending anti-platelet 
therapy increased protection suggesting (often confirmed since) that vascular 
problems continue long after primary treatment for acute disease. 
 
His second most cited paper (343) dealt with assessing the pharmacodynamics, 
pharmacokinetics, and safety of AZD6140, (later called ticagrelor) the first oral, 
reversible adenosine diphosphate (ADP) receptor antagonist to be used clinically [3]. 
Problems associated with clopidogrel and other thienopyridines include patient 
“resistance” i.e. not all patients receiving a standard dose showed adequate 
inhibition (ca. 80%) of the ADP receptor as well as the fact that the activate 
metabolite of clopidogrel reacts covalently with the P2Y12 ADP receptor. This means 
that if surgery is urgently necessary, such as following an accident, clopidogrel 
treatment cannot be rapidly reversed and even if stopped it requires several days 
until enough fresh platelets are formed to reinstate full haemostasis. Thus, reversible 
(i.e. non-covalent) P2Y12 inhibitors make sense, on the one hand to “top up” patients 
with inefficient inhibition by clopidogrel and similar treatment and on the other to treat 
patients where the risk of surgical intervention is high and where ceasing treatment 
leads rapidly to elimination of the inhibitor. 
 
His third most cited paper (208) also falls in this area comparing effects and 
efficiency of AZD6140 with clopidogrel in patients with acute coronary syndrome [4]. 
Again, this refers to their relative efficiency in reducing a tendency to thrombosis and 
the problem of variation in response among patients. Stan also contributed to a long 
series of papers establishing the relative efficacy of P2Y12 inhibitors and their role in 
dosing regimens for patients with or without aspirin as supplementary inhibitor. 
These have contributed in the long term to protecting patients from thrombosis and 
making surgery safer by reducing both bleeding and thrombosis risks. 
 
Ticagrelor (AZD6140) is a cyclopentyl-triazolo-pyrimidine, a new chemical class of 
P2Y12 antagonist that is now approved for use in a wide spectrum of acute coronary 
syndromes. Ticagrelor has a different binding site on P2Y12 from ADP or cangrelor 
(an ADP analogue, making it an allosteric antagonist, with reversible blockage. The 
drug does not need hepatic activation, avoiding the problems with patients with 
genetic variants of the enzyme CYP2C19 and has a longer in vivo half-life so that 
patients need only be dosed once a day giving better compliance. 
 
Since some reversible P2Y12 inhibitors e.g. cangrelor, compete for the same 
receptors as the covalent, irreversible ones (clopidogrel, prasogrel) it could be 
expected that if given first or even simultaneously they might prevent efficient 
irreversible inhibition and this was indeed demonstrated by Stan and his colleagues 
[5]. Although this might have been predicted it was still necessary to establish this 
experimentally because the relative binding constants of cangrelor and the activate 
metabolite of clopidogrel were not known. 
 
Another interesting area of Stan’s research has been the effects of feverfew 
(Tanacetum parthenium) extracts on platelets [6]. Feverfew is an anti-inflammatory 
medicinal herb with a long history of use in “natural” treatment of health problems 
including migraine. The main active principle is parthenolide, now also a promising 
candidate for anti-cancer treatment. Parthenolide is a sesquiterpene lactone that, like 
clopidogrel, is activated by P450 (CYP2C19). However, it is active against signalling 
pathways in cancer stem cells. In platelets it seems to act by inhibiting –SH groups 
(perhaps also disulphide isomerase) involved in signalling pathways. Stan also 
contributed to improved methods for extracting parthenolide from feverfew, an 
important step in preparing pure material for testing biological activity. 
 
In the late 80s and early 90s there was much interest in the development of direct 
anti IIb/IIIa receptor (IIb3) inhibitors to prevent thrombosis and several have been 
successfully applied clinically in acute situations. These are a cyclic peptide based 
on snake venom protein disintegrin sequence (integrilin, eptifibatide) and a 
humanised monoclonal antibody (abciximab) and more recently a small molecule 
inhibitor (tirofiban). However, attempts to develop small molecule antagonists that 
could be used for long term treatment of chronic conditions were unsuccessful in 
clinical trials mainly because they activated the IIb3 so that fibrinogen could cause 
platelet aggregation and activation. Although it was clear that alternative inhibitors 
should be sought that do not activate IIb3 or cause thrombocytopenia via 
neoepitope formation, the pharmaceutical companies have been reluctant to pursue 
this path. Stan and his colleagues did a number of studies with the available anti-
IIb/IIIa inhibitors to explore some of their side effects on platelets. These included the 
investigation of platelet-leukocyte and platelet-monocyte conjugates because 
although platelet aggregation was inhibited, platelet activation and release of 
granules and expression of granule membrane proteins such as P-selectin and 
CD154 were only partially inhibited. Treatment of the conjugates with EDTA 
dissociated the platelets from the nucleated cells but did not dissociate P-selectin or 
CD154 from the platelets. The conclusion reached was that despite inhibiting 
aggregation, conjugate formation was enhanced favouring inflammation and 
thrombosis and providing an explanation for at least some of the (originally at least, 
unexpected) negative clinical effects of this class of IIb/IIIa inhibitor [7]. 
More recently, there has been renewed interest in this problem in the hope of 
developing anti-IIb3 molecules for injection as emergency treatment for 
myocardial infarction to help to disrupt a blocking thrombus. 
 
I have dealt here with some of the main areas of Stan’s research. However, over the 
years he dealt with a great many other aspects of platelet activation and inhibition via 
a wide range of receptors and/or signalling pathways. Although none of these has 
been adapted clinically for a variety of reasons they were (are) nevertheless of 
considerable interest in understanding how platelets work and how their activity is 
regulated in vivo, which is vital for long term development of better platelet activation 
inhibitors. With the development and clinical acceptance of prasugrel and ticagrelor it 
might be argued that optimal inhibitors are already here and certainly any new 
inhibitors will have to show considerable improvements in properties to replace or 
complement these. Even so there may still be scope for improvement, particularly in 
respect of stroke where prevention and treatment still have a long way to go and 
where progress has been somewhat inhibited by the lack of adequate animal models 
as well as considerable differences in physiology. In addition, in the future it may be 
necessary to have inhibitors that affect some aspects of platelet function but not 
others. Hence, research into the effects of other receptor pathways is still of 
considerable interest even if they do not find instant application. 
In the circulation, platelet reactivity is normally regulated by an endothelial 
membrane apyrase (CD39) that destroys ADP released by platelets or erythrocytes 
and thus prevents platelet activation. However, under pathological conditions this 
may not be adequate which is why the P2Y12 receptor inhibitors are effective.  
Platelets are also kept pacified by prostaglandin and NO release from endothelial 
cells. Platelet activation ex vivo where they are no longer exposed to these factors 
may therefore not completely reflect the in vivo situation. Stan and his colleagues 
were interested in defining how platelets were affected by prostaglandins and which 
receptors are involved. In 2011 they demonstrated that platelet responses to PGE1 
and PGE2 are mediated by different prostanoid receptors and in 2012 showed that 
like PGE2, PGE3 interacts with EP3 and EP4 receptors, but not the IP receptor, 
which is responsible for mediating the inhibitory effects of PGE1 [8]. Therefore, the 
overall effect of PGE3 on platelet function, like those of PGE1 and PGE2, reflect a 
balance between effects at both activating and inhibitory receptors. The mechanism 
of PGE3 is particularly interesting because it is derived from omega-3 fatty acids, 
which in the diet are generally shown to have positive effects on the development of 
cardiovascular diseases. The study of platelet prostanoid receptors is relevant to the 
development of new anti-inflammatory drugs because some COX-2 specific 
antagonists appear to affect synthesis of prostaglandins controlling platelet activity 
which was unexpected. 
 
In the years leading up to his retirement Stan was also interested in improved 
methodology for testing ex vivo levels of platelet activation and how these were 
affected by platelet inhibition. A typical approach is the measurement of VASP 
phosphorylation, which is altered, particularly via ADP receptor activation [9]. Thus, 
the levels of VASP phosphorylation can be used to estimate the degree to which the 
P2Y12 receptor has been inhibited and therefore how much the patient is protected. 
This can also be followed by looking at P-selectin expression rates compared to 
controls [10]. 
 
Of course, “No man is an island”, and Stan’s research would not have been possible 
without the large number of colleagues who participated in various capacities, 
clinical, postdocs, graduate students and technicians. Figure 1 shows one of the last 
of these groups from 2010. 
 
Thus, in summary, Stan and his colleagues have contributed largely to an improved 
knowledge of platelet receptors and how these regulate platelet activity. They have 
tested a wide range of different classes of inhibitors and they have studied some of 
the most promising of these in clinical trials. Thus, they have helped to provide data 
on the effectiveness of these inhibitors that was invaluable for determining their 
clinical usefulness.  
 
In this relatively short overview there is not enough space to cite all of Stan’s 
publications and the reader must therefore refer to PubMed or similar to see all of 
these. Those references listed below include particularly relevant or representative 
works. 
 
The author declares that he has no conflicts of interest. 
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Legend to Figure 
 
Figure 1. Stan Heptinstall’s  team in 2010. Postdoctoral researchers Sue Fox, PhD, 
David Iyu, PhD, and Natalie Dovlatova, PhD, and technicians Jane May, Jackie 
Glenn, Ann White, and Andrew Johnson. Other external collaborators are not shown. 
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